Anadys gains on ANA598 Phase II plans

Anadys Pharmaceuticals Inc. (NASDAQ:ANDS) jumped $0.80 (44%) to $2.60 on Friday after announcing late Thursday that it will begin a Phase II trial of ANA598 in combination with Pegasys peginterferon alfa-2a and ribavirin to treat HCV within the next several weeks. Anadys said in March that it would not start a trial of the oral non-nucleoside HCV non-structural protein 5B inhibitor until it completed a transaction or a financing due to the company's low cash reserves. Last month, the company raised $17.5 million in a registered direct offering and announced plans to restructure (See BioCentury Extra, Thursday, June 04, 2009). ...